P149 Validation of the COPD assessment test (CAT) within  -1 antitrypsin deficiency (A1ATD)

Introduction and objectives The COPD Assessment Test (CAT) has recently been validated with a USA cohort as a health status questionnaire (HSQ) for use in chronic obstructive pulmonary disease (COPD). 1 Its purpose is to guide and improve communication between the health care professional and patient and identify key areas for health improvement. Historically, other HSQ have been used in COPD especially the St Georges Respiratory Questionnaire (SGRQ) which has been extensively validated for use in clinical care and trials. However the SGRQ has a complex scoring algorithm and requires several minutes to complete restricting its use in daily clinical practice. 1 2 The CAT was developed as a user friendly, time efficient, easily analysed and reliable HSQ for COPD. We have an extensive database for patients with α-1 Antitrypsin Deficiency (A1ATD) and have an annual review at which the SGRQ is used. We wished to compare CAT with the SGRQ in these patients. Methods 163 consecutive patients with A1ATD attending the Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT) centre were asked to complete both SGRQ and CAT prior to full Lung function and medical review. All patients were clinically stable (at least 6 weeks post exacerbation). SGRQ and CAT scores were compared as well as routine post bronchodilator lung function parameters to determine the relationships. Results 157 patients completed both questionnaires. CAT correlated strongly with SGRQ total score (R2 =0.799, p